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ABSTRACT Understanding which cytosolic domains of the dihydropyridine receptor participate in excitation-contraction (EC)
coupling is critical to validate current structural models. Here we quantiﬁed the contribution to skeletal-type EC coupling of the
a1S (CaV1.1) II-III loop when alone or in combination with the rest of the cytosolic domains of a1S. Chimeras consisting of a1C
(CaV1.2) with a1S substitutions at each of the interrepeat loops (I-II, II-III, and III-IV loops) and N- and C-terminal domains were
evaluated in dysgenic (a1S-null) myotubes for phenotypic expression of skeletal-type EC coupling. Myotubes were voltage-
clamped, and Ca21 transients were measured by confocal line-scan imaging of ﬂuo-4 ﬂuorescence. In agreement with previous
results, the a1C/a1S II-III loop chimera, but none of the other single-loop chimeras, recovered a sigmoidal ﬂuorescence-voltage
curve indicative of skeletal-type EC coupling. To quantify Ca21 transients in the absence of inward Ca21 current, but without
changing the external solution, a mutation, E736K, was introduced into the P-loop of repeat II of a1C. The Ca21 transients
expressed by the a1C(E736K)/a1S II-III loop chimera were ;70% smaller than those expressed by the Ca21-conducting a1C/
a1S II-III variant. The low skeletal-type EC coupling expressed by the a1C/a1S II-III loop chimera was conﬁrmed in the Ca21-
conducting a1C/a1S II-III loop variant using Cd21 (104 M) as the Ca21 current blocker. In contrast to the behavior of the II-III
loop chimera, Ca21 transients expressed by an a1C/a1S chimera carrying all tested skeletal a1S domains (all a1S interrepeat
loops, N- and C-terminus) were similar in shape and amplitude to wild-type a1S, and did not change in the presence of the
E736K mutation or in the presence of 104 M Cd21. Controls indicated that similar dihydropyridine receptor charge movements
were expressed by the non-Ca21 permeant a1S(E1014K) variant, the a1C(E736K)/a1S II-III loop chimera, and the
a1C(E736K)/a1S chimera carrying all tested a1S domains. The data indicate that the functional recovery produced by the a1S
II-III loop is incomplete and that multiple cytosolic domains of a1S are necessary for a quantitative recovery of the EC-coupling
phenotype of skeletal myotubes. Thus, despite the importance of the II-III loop there may be other critical determinants in a1S
that inﬂuence the efﬁciency of EC coupling.
INTRODUCTION
Ca21 signals of skeletal muscle cells are controlled by the
voltage-gated L-type Ca21 channel formed by the dihydro-
pyridine receptor (DHPR), and by the sarcoplasmic reticu-
lum (SR) Ca21 release channel formed by the ryanodine
receptor type 1 (RyR1). The well-established paradigm is
that in response to depolarization, the DHPR produces a
signal that brieﬂy opens the RyR1 channel, leading to the
release of SR-stored Ca21. Signal transmission takes place at
specialized junctions between transverse tubules and SR
membranes. At these junctions, DHPRs in tetrad arrange-
ment juxtapose a single tetrameric RyR1 channel (1–3). The
narrow physical gap between the transverse tubule and the
SR (;12 nm) (2), the large protrusion of foot structure of
the RyR1 channel into the gap (;7 nm) (4), and the overall
molecular dimensions of the DHPR and RyR1 complexes
(5,6), all suggest that the DHPR and RyR1 channels must be
in physical contact. Strong evidence for the formation of a
DHPR-RyR1 complex in myotubes is provided by a recent
freeze-fracture analysis of the molecular determinants that
specify the arrangement of DHPRs in arrays of tetrads op-
posite to RyR1 (7).
The a1S subunit (CaV1.1) of the skeletal DHPR has
the familiar topology of a four-repeat voltage-gated channel
with ﬁve cytosolic domains adjoining the four repeats
(N-terminus, I-II loop, II-III loop, III-IV loop, and C-terminus)
(8–10). Reports made almost 15 years ago (11,12) and re-
ﬁned later (13–17), have suggested that the cytosolic loop
linking repeats II and III, consisting of 132 residues, brings
about the conformational change that opens the RyR1 chan-
nel under the inﬂuence of membrane depolarization. The
II-III loop is commonly viewed as the cell’s version of the
mechanical plunger proposed by Chandler et al. (18), in
which an element of the transverse tubule linked to the
excitation-contraction (EC) -coupling voltage sensor exerts
torque on the SR Ca21 channel. The II-III loop model of EC
coupling is simple, has intuitive appeal, and has received
broad consideration. However, in reality, the signaling
mechanism may be more complex. The prevailing evidence
indicates that interactions between a1S and RyR1 are likely
to involve the II-III loop, but also many other domains of
a1S (7,19–24). Additional complexity is brought about by
a deletion analysis showing that the II-III loop may not
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account entirely for the signaling function of the DHPR (25).
Furthermore, the DHPR b1a subunit is essential for skeletal-
type EC coupling (26–28), and interactions between this
subunit and RyR1 are almost certain (6,29). Hence, the mo-
lecular determinants of the voltage-dependent mechanism by
which the DHPR activates RyR1 may be broader than ini-
tially anticipated by the II-III loop model and are still open to
debate despite unrelenting efforts.
In light of the growing multiplicity of DHPR-RyR1 in-
teractions, here we reinvestigated the contribution of the
cytosolic domains of a1S to skeletal-type EC coupling in
dysgenic (a1S null) myotubes. Previous studies have
focused almost exclusively on the functional identity of
regions within the skeletal II-III loop (14,16,17,25,30,31).
However, a voltage-clamp analysis of the EC-coupling phe-
notype contributed by each of the a1S interrepeat loops, as
well as by the N- and C-terminal domains, has not been
previously conducted. Likewise, the phenotype contributed
by all the cytosolic domains together, as they would be pres-
ent in the intact subunit, has not been documented. Since
a1C does not express skeletal-type EC coupling (14,32), we
focused on chimeras consisting of a1C (CaV1.2) with se-
quences from a1S (CaV1.1), substituting the interrepeat
loops (I-II, II-III, or III-IV) or the N- or C-terminus . We
report that Ca21 entry-independent Ca21 transients of a
magnitude and voltage dependence similar to those ex-
pressed by wild-type (WT) a1S required a chimera with mul-
tiple a1S domains, including the II-III loop. However, the
chimera with the II-III loop alone was insufﬁcient. Some of
these results have been published in abstract form (33,34).
MATERIALS AND METHODS
Identiﬁcation of genotypes
Dysgenic (a1S-null mdg) mice were screened for both wild-type and mutant
alleles of the DHPR a1S gene. Digestion of tail samples and subsequent
veriﬁcation of genotypes by the polymerase chain reaction (PCR) were de-
scribed previously (27).
Primary cultures and cDNA transfection
Cultures of myotubes were prepared from hind limbs of E18 fetuses, as
described previously (35). Cultures were grown at 37C in 8% CO2 gas.
After myoblast fusion (;5 days), the medium was replaced with FBS-free
medium, and CO2 was decreased to 5%. cDNA transfection was performed
during the myoblast fusion stage with the polyamine LT1 (Panvera,
Madison, WI). In addition to the cDNA of interest, cells were cotransfected
with a plasmid encoding the T-cell protein CD8, which is used as
a transfection marker. Transfected myotubes expressing CD8 were
recognized by surface binding of polystyrene beads coated with anti-CD8
antibody (Dynal ASA, Oslo, Norway). Whole-cell analysis of Ca21
currents, charge movements, and Ca21 transients was performed 3–5 days
post-transfection. The numbers of separate myotube cultures that were
transfected and from which data were collected were as follows for Ca21
current, Ca21 transient, and charge movements when applicable: for
nontransfected mdg, 10, 27, and 2; for WT a1S, 7, 3, and none; for
a1S(E1014K), 3, 4, and 2; for WT a1C, 5, 3, and none; for a1C(E736K), 3,
2, and 2; for a1C/a1S N, 3, 3, and none; for a1C/a1S I-II, 4, 4, and none; for
a1C/a1S II-III, 6, 4, and none; for a1C(E736K)/a1S II-III, 3, 2, and 3; for
a1C/a1S III-IV, 4, 3, and none; for a1C/a1S C, 3, 2, and none; for a1C/a1S
all loop, 3, 3, and none; for a1C(E736K)/a1S all loop: 3, 3, and 3; for all
cadmium experiments, 2, 2, and none.
cDNA constructs
Chimeric variants were made by two-step PCR strategies using cDNAs for
rabbit skeletal muscle a1S (residues 1–1873; Genbank No. M23919) and
rabbit cardiac a1C (residues 1–2171; Genbank No. X15539). The PCR
products were subcloned into pCR-Blunt vector (Invitrogen, Carlsbad, CA),
excised by digestion with AgeI/NotI, and cloned into the pSG5 vector
(Stratagene, San Diego, CA) in frame with the ﬁrst 11 residues of the phage
T7 gene 10 protein for antibody tagging. All constructs were sequenced
twice or more at a campus facility.
Domain boundaries and nomenclature
Alignment of a1S and a1C sequences was performed with DNASTAR
(Madison, WI) using the Jotun-Hein method. a1S N corresponds to residues
1–51 and replaced a1C N residues 1–154; a1S I-II loop corresponds to
residues 335–432 and replaced a1C I-II loop residues 436–554; a1S II-III
loop corresponds to residues 667–799 and replaced a1C II-III loop residues
789–930; a1S III-IV loop corresponds to residues 1067–1120 and replaced
a1C III-IV loop residues 1188–1241; a1S C corresponds to residues 1328–
1873 and replaced a1C C residues 1507–2171.
a1C/a1S N
This chimera consists of a1S residues M1–K51 fused to the N-terminus of
a1C residues P155–L2171. The N-terminus of a1S was ampliﬁed from full-
length a1S and corresponds to residues 1–51. The second-step PCR product
containing the a1S N-terminus and part of a1C domain I was fused to the
pSG5 a1C vector using NheI/SacI sites.
a1C/a1S I-II
This chimera consists of a1C residues M1–S435 fused to the N-terminus of
a1S residues G335–R432 fused to the N-terminus of a1C residues V555–
L2171. The I-II loop of a1S was ampliﬁed from full-length a1S and
corresponds to residues 335–432. The second-step PCR product containing
the a1S I-II loop and part of a1C domains I and II was fused to the pSG5
a1C vector using BamHI/XhoI sites.
a1C/a1S II-III
This chimera consists of a1C residues M1–D788 fused to the N-terminus of
a1S residues A667–T799 fused to the N-terminus of a1C residues I931–
L2171. To replace the II-III loop, aHindIII site at nucleotide 2561 and a SpeI
site at nucleotide 3203 were introduced into full-length a1C as silent
mutations. The II-III loop of a1S was ampliﬁed from full-length a1S, and
corresponds to residues 667–799. The second-step PCR product containing
the a1S loop and part of a1C domain III was fused to the pSG5 a1C vector
using HindIII/SpeI sites.
a1C/a1S III-IV
This chimera consists of a1C residues M1–V1187 fused to the N-terminus
of a1S residues T1067–F1120 fused to the N-terminus of a1C residues
E1242–L2171. The III-IV loop of a1S was ampliﬁed from full-length a1S
and corresponds to residues 1067–1120. The second step PCR product
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containing the a1S III-IV loop and part of a1C domains III and IV was fused
to the pSG5 a1C vector using SpeI/SacII sites.
a1C/a1S C
This chimera consists of a1C residues M1–M1506 fused to the N-terminus
of a1S residues D1328–P1873. The C-terminus of a1S was ampliﬁed from
full-length a1S using a forward primer containing a 59 overhang of the
C-terminal end of a1C domain IV up to the BclI restriction site, and a reverse
primer at the stop codon of a1S. The PCR product containing the a1S
C-terminus and part of a1C domain IV was fused to the pSG5 a1C vector
using BclI/NotI sites.
a1C/a1S all loop (N, I-II, II-III, III-IV, C)
This chimera consists of fusions of the following peptide fragments in se-
quential order from N- to C-terminus: a1S(M1–K51)/a1C(P155–S435)/
a1S(G335–R432)/a1C(V555–D788)/a1S(A667–T799)/a1C(I931–V1187)/
a1S(T1067–F1120)/a1C(E1242–M1506)/a1S(D1382–P1873). This chi-
mera was made by a cut-and-paste method using the chimeras and restriction
sites indicated above.
a1C(E736K)
This domain II pore mutation was described elsewhere (36) and consists
of a replacement of the glutamate residue at position 736 by lysine. We
designed a 37-base antisense primer that introduced a mismatch at nu-
cleotide 2397 (g2397a), and a sense primer that annealed before the BamHI
site of a1C. The PCR product was cloned into the pSG5 a1C vector at
BamHI/EcoRI sites.
a1S(E1014K)
This domain III pore mutation consists of replacement of a glutamate residue
at position 1014 by lysine, and was previously made and described else-
where (25).
Whole-cell voltage clamp
Whole-cell recordings were performed with an Axopatch 200B ampliﬁer
(Axon Instruments, Foster City, CA). Effective series resistance was com-
pensated up to the point of ampliﬁer oscillation with the Axopatch circuit.
All experiments were performed at room temperature. Patch pipettes had
a resistance of 1–3 MVwhen ﬁlled with the pipette solution. To obtain Ca21
conductance curves, cells were maintained at a holding potential of 40
mV, and depolarized in ascending order every 3 s. The pulse duration was
500 ms and was changed in 5-mV increments up to 185 mV. To obtain
Ca21 transient curves, cells were maintained at 40 mV and depolarized in
descending order every 30 s to permit recovery of the resting ﬂuorescence.
The pulse duration was 200 ms and was changed in 20-mV decrements from
190 mV to –30 mV. To obtain charge movement curves, we used a P/4
protocol with a long prepulse to inactivate Na1-channel ionic and gating
currents (25). The pulse protocol was as follows. The command voltage was
stepped from a holding potential of80 mV to30 mV for 698 ms, to50
mV for 5 ms, to the test potential for 50 ms, to 50 mV for 50 ms, and then
to the 80 mV holding potential. Test potentials were applied in decreasing
order every 10 mV from 1100 to –80 mV. The waiting period between test
pulses was 10 s.
Confocal ﬂuorescence microscopy
Ca21 transients were measured by confocal line scanning at room
temperature. Cells were loaded with 5 mM ﬂuo-4 acetoxymethyl ester
(Molecular Probes, Eugene, OR) for ;1 h at room temperature. Cells were
viewed with an inverted IX20 Olympus microscope with a 203 (NA 1.4)
objective and a Fluoview confocal attachment (Olympus, Melville, NY).
The 488 nm line provided by a 5 mWArgon laser was attenuated to 6% with
neutral density ﬁlters. Line scans were acquired at a speed of 2.05 ms per
line. All line scans consisted of 1000 lines at a width of 512 pixels. The
spatial dimension of the line scan was 30–60 mm , and covered the entire
width of the myotube. Locations selected for line scans were devoid of
nuclei and had a low resting ﬂuorescence. Line scans were synchronized to
start 100 ms before the onset of the depolarization for voltage-clamp
experiments. The time course of the space-averaged ﬂuorescence intensity
change was estimated as described elsewhere (26,27) and is reported in
DF/F units. The peak-to-peak noise in the baseline ﬂuorescence averaged
;0.1 DF/F units. Image analyses were performed with NIH Image software
(National Institutes of Health, Bethesda, MD).
Solutions
For Ca21 currents and Ca21 transients, the external solution was (in mM)
130 TEA methanesulfonate, 10 CaCl2, 1 MgCl2, 10
3 TTX, and 10 HEPES
titrated with TEA(OH) to pH 7.4. The pipette solution consisted of (in mM)
140 Cs aspartate, 5 MgCl2, 0.1 EGTA (when Ca
21 transients were recorded)
or 5 EGTA (when only Ca21 currents were recorded), and 10 MOPS titrated
with CsOH to pH 7.2. For charge movements, the internal solution was
(inmM) 120NMG (N-methyl glucamine)-Glutamate, 10HEPES-NMG, and
10 EGTA-NMG, pH 7.3. This solution produced a more reliable block of
the outward ionic current than the internal solution used for Ca21 currents.
The external solution was supplemented with 0.5 mM CdCl2 to block back-
ground Ca21 currents present in mdg myotubes, 0.5 mM LaCl3 to increase
pipette seal resistance and 0.05 mM TTX to block residual Na1 current.
Curve ﬁtting
The voltage dependence of the Ca21 conductance, charge movements, and
sigmoidal ﬂuorescence-voltage relationships were ﬁtted with a standard
Boltzmann equation:
A ¼ Amax=ð11 expððV  V1=2Þ=kÞÞ; (1)
where V (in mV) is the test potential, Amax isGmax,Qmax, orDF/Fmax, V1/2 (in
mV) is the midpoint potential, and k (in mV) is the slope factor. For bell-
shaped ﬂuorescence-voltage curves, the Boltzmann equation was modiﬁed
as follows:
DF=F ¼½ðV  VrÞ=k9
3½DF=Fmax=ð11 expððV  V1=2Þ=kÞÞ;
(2)
where Vr (in mV) is a constant that accounts for the decrease in Ca21
transient amplitude at positive potentials, and k9 (in mV) is an empirical
scaling factor (26,27). Other parameters are the same as in Eq. 1. Parameters
of a ﬁt of averages of many cells (population average) are shown in the
ﬁgures. Parameters of the ﬁt of individual cells are shown in tables. Param-
eters of the ﬁt of the population average differed slightly from the mean of
the ﬁt of individual cells. The latter parameters generated theoretical curves
that were a better ﬁt with the average data and, for that reason, were used in
the ﬁgures. Analysis of variance (ANOVA) was performed with Analyze-it
(Leeds, UK).
RESULTS
Recovery of voltage- or Ca21 entry-dependent
EC coupling in dysgenic myotubes
Studies have shown that a1C is targeted to EC-coupling
junctions in cultured skeletal myotubes, and that the Ca21
DHPR a1S EC Coupling 245
Biophysical Journal 89(1) 243–255
current generated by a1C can trigger Ca21 transients by
Ca21-dependent activation of RyR1 (31,32). Chimeras with
a1C in the backbone also activate Ca21 transients by
a similar mechanism when expressed in skeletal myotubes
(11,14). Hence, Ca21 release induced by the Ca21 current is
inherent to chimeras of a1C, and this component needs to be
carefully separated from the release of interest triggered by
mechanical DHPR-RyR1 coupling. To exclude the compo-
nent of the Ca21 transient triggered by the Ca21 current
without changing the external solution, we mutated the
conserved glutamate E736 in the P-loop of repeat II of a1C,
previously shown to be critical for Ca21 permeation (36).
Fig. 1 shows the EC coupling and Ca21 current character-
istics of a1C(E736K) and a1S(E1014K), localized in the
P-loop of repeat III of a1S (25,37). The top traces show
representative Ca21 transients and Ca21 currents at130 mV,
with the pore mutants depicted by shaded traces. In this and
other ﬁgures, the displayed Ca21 transients and Ca21 cur-
rents were obtained with different protocols and different
internal solutions (see Materials and Methods). For Ca21
currents, we used 500-ms depolarizations in a highly buff-
ered internal solution (5 mM EGTA). These conditions
permitted the determination of the time course of inactivation
while maintaining a low cytosolic Ca21 at all potentials. For
Ca21 transients, we used 200-ms depolarizations in a lightly
buffered internal Ca21 solution (0.1 mM EGTA). These con-
ditions limited SR Ca21 release, increased the rate of resting
Ca21 recovery, and increased the intensity of the ﬂuores-
cence signal. In all cases, the external Ca21 concentration was
10 mM. WT a1S expressed slow-activating/noninactivating
Ca21 currents typical of cultured normal primary myotubes
(35). In contrast, WT a1C expressed fast-activating/slow-
inactivatingCa21 currents, in agreementwith previous results
in mdg myotubes (11,32,38). The degree of inactivation of
a1C was variable, and to some extent varied with the Ca21
current density, consistent with Ca21-entry-dependent in-
activation of a1C investigated by others in myotubes (16).
Both a1C and a1S recovered a Ca21 current density close to
that of normal myotubes reported elsewhere (35). Inward
currents expressed by the pore mutants were drastically re-
duced. In the case of a1S(E1014K), inward current was
undetectable (,0.1 pA/pF), consistent with previous results
(25). In the case of a1C(E736K), the inward current at 130
mVwas reduced;180-fold compared toWTa1C, consistent
FIGURE 1 Ca21 currents and Ca21 transients expressed
by a1S and a1C variants. Columns show representative
mdg myotubes transfected with WT a1S, WT a1C, and
variants carrying pore mutations, namely a1S (E1014K)
and a1C (E736K). Shaded traces and shaded symbols
correspond to the pore mutant form of the variant indicated
above each column. The top trace corresponds to the
spatial integral of the confocal Ca21 transient in DF/F
units in response to a 200-ms depolarization to 130 mV
from a holding potential of 40 mV. The second row of
traces corresponds to the Ca21 current elicited during
a 500-ms depolarization from a holding potential of
40 mV to 130 mV. The Ca21 transients and Ca21
currents shown in this and other ﬁgures were obtained
with different protocols (see text, especially Materials and
Methods). Population averages of the Ca21 current-
voltage curves are located centrally. These were obtained
by depolarizing transfected myotubes in 5-mV increments
from a holding potential of 40 mV for 500 ms. At the
bottom are Ca21 transient-voltage curves for population
averages in response to a 200-ms depolarization from 40
mV to the indicated potentials. The population averaged
ﬂuorescence-voltage curves for a1S and a1S(E1014K)
were ﬁt with Eq. 1, and those obtained in myotubes
expressing a1C and a1C(E736K) were ﬁt with Eq. 2.
Curves were ﬁt with the following parameters (DF/Fmax in
DF/F units, V1/2 in mV, and k in mV, respectively): for
a1S: 2.6, 5.3, and 11.7; for a1S(E1014K), 2.6, 6.4, and
7.8; for a1C, 1.2, 20.6, and 6.1; for a1C(E736K), 0,
19.7, and 20. For a ﬁt of parameters by cell and number
of cells included in the ﬁt, see Table 1.
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with determinations in oocytes (36). The reduction was less
pronounced if calculations are based on the maximum Ca21
conductance, Gmax, expressed by the conducting and non-
conducting variants (see Tables 1 and 2). This is because the
Gmax of a1S(E1014K) and a1C(E736K) is dominated by the
conductance of the outward current (Fig. 1, middle panels).
The latter is a mixture of outward current through the mutant
Ca21 channel and background outward currents unaffected
by the mutation.
Ca21 transients expressed by the conducting and non-
conducting variants were obtained by line-scan integration
of confocal ﬂuo-4 ﬂuorescence in myotubes held under
voltage-clamp conditions. As indicated by the superimposed
traces at the top of Fig. 1, the pore mutation a1S(E1014K)
had a minimal effect on the time course of the Ca21 transient
compared to WT a1S. This result is in agreement with pre-
vious observations (25,37), and conﬁrms expression of a
bona ﬁde skeletal-type EC-coupling phenotype. In contrast,
the amplitude of the Ca21 transient evoked by a1C(E736K)
was severely depressed compared to WT a1C. The bottom
graphs of Fig. 1 show the relationship between the amplitude
of the Ca21 transient and the magnitude of the depolarization,
in the presence and absence of pore mutations. The Ca21
transient amplitude in these plots was measured just before
the end of a 200-ms depolarization, and thus excluded
Ca21 release triggered by the tail current, which was pro-
minent in some myotubes. For a1S and a1S(E1014K),
the expressed Ca21 transients had a sigmoidal voltage-
dependence with saturation at potentials more positive than
130 mV. Furthermore, there was good agreement between
the two sets of data. We interpreted this result as an indica-
tion that the EC coupling expressed by a1S or a1S(E1014K)
was entirely Ca21-entry-independent. In contrast, Ca21
transients recovered by a1C were smaller in magnitude,
reached a maximum at ;130 mV, and decreased at more
positive potentials. This biphasic behavior gives rise to a
bell-shaped ﬂuorescence-voltage curve that mirrors the bell-
shaped dependence of the Ca21 current-voltage curve (see
Fig. 1, middle panel). This result agrees with previous
determinations in dysgenic myotubes (32), and suggests that
Ca21 transients may be triggered by the Ca21 current via
a Ca21-dependent mechanism. Consistent with this interpre-
tation, the pore mutant a1C(E736K) failed to express a
detectable Ca21 transient. The changes in ﬂuorescence in
myotubes expressing WT a1C may also reﬂect changes in
cytosolic Ca21 produced directly by the Ca21 current. The
contribution of the Ca21 current to the cell ﬂuorescence was
determined previously in myotubes treated with ryanodine
(27). For cells with a comparable Ca21 current density, we
found that the contribution was,0.25DF/F at130 mV (27).
In this study, the Ca21 transient expressed by WT a1C at
130mVwas;1.3DF/F (Table 1). For this reason,webelieve
that the Ca21 current expressed byWT a1C contributed only
modestly to the overall cell ﬂuorescence.
Incomplete recovery of skeletal-type EC coupling
by the a1S II-III loop revealed by pore mutations
that eliminate inward Ca21 current
Ca21 currents and transients expressed by chimeras consist-
ing of a1C carrying each of the cytosolic domains of a1S,
namely the N-terminal, I-II loop, II-III loop, III-IV loop, or
C-terminal domains, are shown in Fig. 2. Coordinates of
skeletal domains donated to a1C, and of homologous
regions removed from a1C, are described in Materials and
Methods. The top traces correspond to inward Ca21 currents
for depolarizations to –30 mV and 130 mV in dysgenic
myotubes expressing each of the ﬁve indicated chimeras.
All chimeras expressed high-density, fast-activating, and
slow-inactivating Ca21 currents typical of WT a1C when
expressed in myotubes. Furthermore, the ﬁtted Gmax was sta-
tistically similar to that of a1C or a1S (Table 1). Two
chimeras, that carrying the N-terminal domain (labeled a1C
N) and that carrying the II-III loop (labeled a1C/a1S II-III),
expressed Ca21 current at a density higher than that of
WT a1C, although the difference was not signiﬁcant. Repre-
sentative Ca21 transients at 130 mV, and the voltage
dependence of the Ca21 transient amplitude measured at the
TABLE 1 Ca21 conductance and Ca21 transients expressed by a1C/a1S chimeras in dysgenic (mdg) skeletal myotubes
Gmax (pS/pF) V1/2 (mV) k (mV) DF/Fmax V1/2 (mV) k (mV)
NT mdg 20 6 3* (27) 4 6 5* 19.5 6 7.1* —(25) — —
WT a1S 163 6 13 (14) 38 6 2 6.5 6 0.7 2.7 6 0.4 (5) 7 6 2 8.6 6 1.1
WT a1C 152 6 27 (10) 19 6 3 7.1 6 0.7 1.3 6 0.4* (6) 24 6 3* 5.9 6 1.1
a1C/a1S N 213 6 50 (7) 18 6 3 6.3 6 1.2 0.7 6 0.2* (7) 26 6 10 11.0 6 3.0
a1C/a1S I-II 140 6 35 (10) 21 6 2 9.6 6 0.5 1.1 6 0.3* (8) 19 6 4 7.1 6 1.0
a1C/a1S II-III 208 6 29 (15) 11 6 2 5.4 6 0.7 2.5 6 0.9 (7) 1 6 3 3.3 6 1.0*
a1C/a1S III-IV 153 6 27 (9) 9 6 3 6.8 6 0.8 1.3 6 0.4* (6) 2 6 2 4.8 6 0.8*
a1C/a1S C 151 6 26 (12) 13 6 2 6.3 6 0.5 1.0 6 0.3* (5) 7 6 7 3.1 6 1.5*
a1C/a1S all loop 121 6 25 (5) 11 6 4 6.2 6 1.0 2.2 6 0.6 (8) 9 6 5 8.7 6 1.9
Values are mean 6 SE of Boltzmann parameters ﬁtted to each cell, with the number of cells indicated in parentheses. DF/Fmax, V1/2, and k are parameters
of the Boltzmann ﬁt to each cell with either Eq. 1 or Eq. 2, as indicated in the text. Changes in ﬂuo-4 ﬂuorescence were not detected at any test potential
(30 to 190 mV) in nontransfected dysgenic myotubes (NT mdg).
*Parameters with one-way ANOVA signiﬁcance p , 0.05 compared to myotubes expressing WT a1S.
DHPR a1S EC Coupling 247
Biophysical Journal 89(1) 243–255
end of a 200-ms depolarization, are shown in the bottom
graphs of Fig. 2. For reference, the shaded lines in the
plots indicate the ﬁtted ﬂuorescence-voltage relationship of
myotubes expressing WT a1S and WT a1C described
above. The II-III loop chimera consistently expressed Ca21
transients that were much larger in amplitude than those
expressed by the other chimeras. Furthermore, only the II-III
loop chimera expressed a ﬂuorescence-voltage relationship
that was sigmoidal like that of WT a1S. All other chimeras
expressed ﬂuorescence-voltage relationships that were bell-
shaped like that of WT a1C, indicative of a Ca21-dependent
mechanism. The bell-shaped voltage dependence is partic-
ularly prominent for the III-IV loop and the C-terminal
domain chimeras. Furthermore, in these cases there was
a signiﬁcant negative shift in midpoint potential compared
to WT a1C. The shifts were consistent with differences
in midpoint potential found for the Ca21 conductance
described in Table 1. In summary, only the a1C/a1S II-III
loop chimera expressed Ca21 transients with a sigmoidal
ﬂuorescence-voltage curve indicative of skeletal-type
EC coupling. This result is consistent with previous
observations, which have suggested that the II-III loop is
a critical domain for skeletal-type EC coupling (11,13–
17,30,32). Other domains of a1S, namely the III-IV loop
and the C-terminal domain, affected channel gating by
shifting Ca21 current activation to more negative potentials,
resulting in a concurrent shift in the voltage dependence
of the Ca21 transient. Furthermore, the skeletal N-terminal
domain and the I-II loop do not appear to inﬂuence the
Ca21-dependent EC-coupling phenotype in a signiﬁcant
manner.
To examine the extent of recovery of the skeletal
phenotype by the II-III loop chimera, we investigated Ca21
transients elicited by the II-III loop chimera in the presence
FIGURE 2 Ca21 currents and Ca21 transients expressed by a1C/a1S chimeras. Columns show representative mdgmyotubes transfected with the identiﬁed
a1C/a1S chimeras. Nomenclature and domain boundaries for the chimeras are described in Materials and Methods. The top traces correspond to Ca21 currents
from the same cell in response to a 500-ms depolarization from a holding potential of40 mV to –30 mV (no current) and to130 mV (near maximum inward
current). Population averages of the Ca21 current-voltage curves are located centrally. These were obtained by depolarizing transfected myotubes in 5-mV
increments from a holding potential of40 mV for 500 ms. The traces in the middle correspond to confocal Ca21 transients in mdgmyotubes expressing each
of the chimeras in DF/F units in response to a 200-ms depolarization to130 mV from a holding potential of40 mV. At the bottom are Ca21 transient-voltage
curves for population averages in response to a 200-ms depolarization from 40 mV to the indicated potentials. The shaded traces without data in each graph
correspond to the ﬁtted voltage dependence of WT a1S and WT a1C from Fig. 1. The ﬂuorescence-voltage curves for all a1C/a1S chimeras were ﬁt with
Eq. 2, except that obtained in myotubes expressing a1C/a1S II-III, which was ﬁt with Eq. 1. Curves (black) were ﬁt with the following parameters (DF/Fmax
in DF/F units, V1/2 in mV, and k in mV, respectively): for a1C/a1S N, 0.5, 16.7, and 10.0; for a1C/a1S I-II, 1.3, 20.0, and 9.9; for a1C/a1S II-III, 2.4, 2.8, and
4.9. For a1C/a1S III-IV, 1.0, 1.2, and 4.5; and for a1C/a1S C, 0.8, 4.9, and 3.9.
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of the a1C(E736K) pore mutation. For the sake of clarity, we
refer to this mutation as E736K in all cases even though
the actual coordinate will differ for some chimeras. The left
panel of Fig. 3 shows representative Ca21 transients and
Ca21 currents expressed by the a1C(E736K)/a1S II-III loop
chimera compared to the Ca21 conducting variant at 130
mV. Current-voltage relationships and ﬂuorescence-voltage
relationships are shown immediately below. Shaded areas
are reserved for the pore mutant. Inward Ca21 currents were
severely curtailed in the a1C(E736K)/a1S II-III chimera
compared to the Ca21-conducting variant. Furthermore,
inward current was blocked to the same extent as with
a1C(E736K). This can be readily appreciated by comparing
current-voltage curves in Figs. 1 and 3, and by the param-
eters of the conductance ﬁt. Table 1 shows data for WT a1C
and a1C/a1S II-III, and Table 2 for a1C(E736K) and
a1C(E736K)/a1S II-III. Based on these results, the mutation
was deemed useful for removing a component of the Ca21
transient of the II-III loop chimera triggered by the Ca21
current, if such a component was present. Quite surprisingly,
Ca21 transients expressed by the a1C(E736K)/a1S II-III
loop chimera were severely depressed relative to those
expressed by the Ca21-conducting a1C/a1S II-III loop
variant. This can be appreciated in the noticeably small Ca21
transient shown at the top of Fig. 3 for a representative
myotube expressing a1C(E736K)/a1S II-III, and by the
ﬂuorescence-voltage relationship at the bottom of Fig. 3. At
face value, the data suggests that the II-III loop chimera relies
heavily on external Ca21 for activation of SR Ca21 release,
and that the voltage-dependent skeletal-type component is
minor. However, other explanations must be considered
also. It is possible that a1C/a1S chimeras are only partially
functional, and, as a consequence, none of them are able to
rescue the skeletal phenotype to the same extent as WT a1S.
Also, the charge movement density expressed by the II-III
chimera may be inherently low, and hence unable to rescue
a substantial skeletal-type component. Finally, the E736K
mutation in repeat II may have adversely affected skeletal-
type EC coupling. The latter is troublesome since it is known
that the E1014K charge reversal eliminates high-afﬁnity
Ca21 binding to the a1S subunit (39). The Ca21-binding site
in the pore region could be the Ca21-binding site identiﬁed
as critical for the DHPR voltage sensor (40,41). In what fol-
lows, we tested these alternatives.
FIGURE 3 Full restoration of skeletal-type EC coupling
by the all loop chimera and partial restoration by the II-III
loop chimera. Columns show representative mdg myo-
tubes transfected with the a1C/a1S II-III loop chimera
and a1C/a1S all loop chimera, both in the presence and
absence of the pore mutation E736K. Shaded traces and
shaded symbols correspond to pore mutants. The top traces
correspond to the spatial integral of the confocal Ca21
transient in DF/F units in response to a 200-ms depolar-
ization to 130 mV from a holding potential of 40 mV.
The second row of traces corresponds to the Ca21 current
elicited during a 500-ms depolarization from 40 mV to
130 mV. Population averages of the Ca21 current-voltage
curves are located centrally. These were obtained by
depolarizing transfected myotubes in 5-mV increments
from a holding potential of 40 mV for 500 ms. At the
bottom are Ca21 transient-voltage curves for population
averages in response to a 200-ms depolarization from 40
mV to the indicated potentials. All ﬂuorescence-voltage
curves were ﬁt with Eq. 1. Curves were ﬁt with the fol-
lowing parameters (DF/Fmax in DF/F units, V1/2 in mV,
and k in mV, respectively): for a1C/a1S II-III, 2.4, 2.8,
and 4.9; for a1C(E736K)/a1S II-III, 0.9, 17.1, and 15.5;
for a1C/a1S all loop, 2.1, 1.7, and 10.9; for a1C(E736K)/
a1S all loop: 2.1, 14.3, and 8.
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To determine if the tested a1C/a1S chimeras were
broadly EC-coupling-defective, we investigated the behavior
of a1C/a1S all loop, a chimera consisting of a1C and all
the cytoplasmic elements of a1S characterized in Fig. 2,
namely the N-terminal, I-II loop, II-III loop, III-IV loop, and
C-terminal domains. If chimeras are defective in general,
such a defect should also be present in a chimera containing
the II-III loop and the rest of the skeletal cytoplasmic
elements. Alternatively, if the a1C/a1S II-III loop chimera
was partially defective due to the absence of critical skeletal
elements, the a1C/a1S all loop chimera should recover the
skeletal phenotype more effectively. These results are shown
in the right panel of Fig. 3. The a1C/a1S all loop chimera
expressed Ca21 currents with a fast activation and slow
inactivation, typical of WT a1C and all tested a1C/a1S
chimeras. Furthermore, the Ca21 current density was not
signiﬁcantly different from that of the other chimeras (Table
2), and as shown by the current-voltage curves, the E736K
pore mutation curtailed the bulk of the inward Ca21 current.
Signiﬁcantly, the voltage dependence of the Ca21 transients
was sigmoidal for both the Ca21-conducting a1C/a1S all
loop and for the poorly conducting a1C(E736K)/a1S all
loop chimeras. The maximum ﬂuorescence at large positive
potentials was also the same. This is indicated by the traces
of cell ﬂuorescence at 130 mV in separate representative
myotubes shown at the top of Fig. 3, and by the ﬂuorescence-
voltage relationships at the bottom of Fig. 3. The ﬁtted
Boltzmann parameters indicated a small difference in mid-
point potential; however, the difference was not signiﬁcant.
Parameters of the ﬁt of the voltage dependence of Ca21
transients are shown in Table 1 for a1C/a1S all loop and in
Table 2 for a1C(E736K)/a1S all loop. From the similarity in
shape and maximum Ca21 ﬂuorescence at large potentials,
we concluded that this pair of chimeras recapitulated well the
behavior of WT a1S and a1S(E1014K) described above. To
determine effectiveness of recovery of the skeletal-type
EC-coupling components by the II-III loop and all loop
chimeras, we compared the behavior of a1C(E736K)/a1S all
loop and a1C(E736K)/a1S II-III loop in terms of the
maximum amplitude of the Ca21 transients elicited at large
positive potentials (Table 2). The all-skeletal loop chimera
recovered a DF/Fmax statistically similar to that of
a1S(E1014K), and ;2.4-fold higher than that of the II-III
loop chimera (t-test signiﬁcance ,0.05). Hence the all loop
chimera was more effective than the II-III loop chimera in
recovery of a skeletal EC-coupling component. The results
show that it is possible to design an a1C/a1S chimera with
a phenotype similar to WT a1S, and that a1C/a1S chimeras
are not inherently EC-coupling-defective. Evidently, several
cytoplasmic loops of a1S, not only the II-III loop, are
required for a quantitative recovery of the EC-coupling
phenotype.
Fig. 4 shows normalized charge movement density (fC/
pF) expressed by the II-III loop chimera, the all loop
chimera, and the two WT constructs. We carried out a
standard gating current protocol (25) in myotubes expressing
variants carrying the pore mutation. This reduced the ionic
current, and hence increased the success of the measurement.
The traces in the insets show the transient outward ON
current at the start of a 50-ms test voltage step to 160 mV
followed by inward OFF current at the end of the voltage
step as charges return to the original position. The complete
pulse protocol (see Materials and Methods) included a 698-
ms prepulse depolarization to 30 mV to remove immobi-
lization-sensitive components of the gating current unrelated
to the DHPR, and pretest P/4 pulses to eliminate linear
components unrelated to voltage sensors. The graphs show
normalized charge density-voltage relationships obtained by
integration of the OFF component which, in our hands, was
less contaminated by residual ionic current than the ON
component. The main contaminant of the ON component
was an outward current, presumably from a K1 channel, that
was not always blocked by the pipette solution. In all cases,
the OFF charge increased in a sigmoidal fashion starting
at ;40 mV and saturated at potentials more positive
than 160 mV. Data were adequately ﬁt by a Boltzmann
equation (Eq. 1). In nontransfected myotubes, we detected
a small background charge with a maximum density of ;1
fC/pF, similar to that reported previously (25). The average
charge movement density of nontransfected cells is shown
TABLE 2 Ca21 conductance, Ca21 transients, and charge density expressed by pore mutants in dysgenic (mdg) skeletal myotubes
Gmax(pS/pF) V1/2(mV) k(mV) DF/Fmax V1/2 (mV) K(mV) Qmax (fC/pF) V1/2 (mV) k(mV)
NT mdg 20 6 3 (27) 4 6 5 19.5 6 7.1 — (25) — — 1.4 6 0.1* (10) 5 6 4 12.0 6 1.2
a1S(E1014K) 48 6 12 (7) 23 6 14 16.2 6 3.9 2.6 6 0.4 (11) 7 6 4 9.3 6 1.0 4.7 6 0.8 (9) 10 6 2 17.8 6 0.8
a1C(E736K) 25 6 6 (7) 21 6 3 13.2 6 1.9 — (5) — — 5.9 6 1.3(4) 5 6 4 18.1 6 0.8
a1C(E736K)/a1S II-III 43 6 7 (7) 6 6 3 10.7 6 1.5 0.9 6 0.2* (7) 20 6 7 12.9 6 2.7 5.8 6 0.9 (7) 12 6 4 21.2 6 1.9
a1C(E736K)/a1S all loop 44 6 9 (8) 44 6 14 18.7 6 3.8 2.2 6 0.6 (8) 11 6 5 9.0 6 2.1 4.5 6 0.6 (4) 12 6 6 17.4 6 1.8
Values are mean 6 SEM of Boltzmann parameters ﬁtted to each cell, with the number of cells indicated in parenthesis. Gmax, DF/Fmax or Qmax, V1/2, and k
are parameters of the Boltzmann ﬁt to each cell with Eq. 1. Changes in ﬂuo-4 ﬂuorescence were not detected at any test potential in NT mdg and
a1C(E736K)-expressing myotubes. Parameters for conductance and ﬂuorescence of NT mdg myotubes are the same as in Table 1.
*Parameters with one-way ANOVA signiﬁcance p , 0.05 compared to myotubes expressing a1S(E1014K). Using the mean Qmax provided in the table, the
ratio (DF/Fmax)/Qmax was 0.55 6 0.08 for a1S(E1014K) (n ¼ 11); 0.16 6 0.04 for a1C(E736K)/a1S II-III (n ¼ 7); and 0.45 6 0.13 for a1C/a1S all loop
(n ¼ 8). The ratio for a1C(E736K)/a1S II-III was signiﬁcantly lower (t-test signiﬁcance p , 0.05) than that of a1S(E1014K) or that of a1C(E736K)/a1S
all loop.
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by the line without data, and the parameters of the ﬁt are
shown in Table 2. The maximum charge-movement densities
expressed by the a1C(E736K)/a1S II-III loop chimera,
the a1C(E736K)/a1S all loop chimera, a1C(E736K), and
a1S(E1014K) were statistically similar (Table 2). These
values agreed with previous determinations in dysgenic
myotubes expressing WT a1C and WT a1S (12,25). The
results show that DHPR voltage-sensor density was not a
confounding factor in our studies .
Incomplete recovery of skeletal-type EC coupling
by the a1S II-III loop revealed by Cd21 block of
inward Ca21 current
Is the reduced activity of the a1C(E736K)/a1S II-III loop
chimera a consequence of the E736K mutation? To answer
this critical question, in Fig. 5 we compared Ca21 transients
expressed by WT a1S and the Ca21-conducting II-III loop
and all loop chimeras in the presence of external Cd21 to
block the inward Ca21 current. Titrations indicated that 104
M, but not 106 M Cd21, blocked the Ca21 conductance to
the same extent as the pore mutations. This is shown in Table
3, with control data in the absence of Cd21 in Table 1. Ca21
currents and Ca21 transients in control external solution and
in external solution supplemented with 104 M Cd21 are
shown for WT a1S, a1C/a1S II-III loop and a1C/a1S all
loop in left, center, and right panels as indicated. Shaded
traces and symbols are reserved for myotubes in external
solution containing Cd21. Inward Ca21 currents were se-
verely curtailed by 104 M Cd21 in all cases. This can be
readily appreciated from the insets of Ca21 currents at 130
mV, and by comparing current-voltage curves in the pres-
ence and absence of the blocker. It is signiﬁcant to observe
that Ca21 transients in the presence of Cd21 reproduced the
same phenotype as those seen in the presence of the pore
mutations. The Ca21 transients expressed by the a1C/a1S
II-III loop chimera were severely depressed in the presence
of the Ca21 current blocker. However, the Ca21 transients
expressed by WT a1S and the a1C/a1S all loop chimera
were not depressed by 104 M Cd21. This can be appre-
ciated in the Ca21 transients shown as insets for a represen-
tative myotube expressing the indicated construct, and by the
ﬂuorescence-voltage relationship in the center of each panel
in Fig. 5. The results are further conﬁrmed by the correlation
FIGURE 4 Charge movement density expressed a1C/
a1S chimeras carrying pore mutations. Graphs show the
population-averaged voltage dependence of the OFF
charge in femto-Coulombs normalized to the linear
membrane capacitance of each cell in pico-Farads. The
OFF charge was obtained by integration of the OFF charge
movement current at the end of a 50-ms test pulse after on-
line subtraction of the linear component. Measurements
were made in mdgmyotubes transfected with the indicated
constructs using a pulse protocol and external and pipette
solutions described in Materials and Methods. The shaded
trace in each graph corresponds to the ﬁt of the population
averaged charge movement of nontransfected dysgenic
myotubes. Insets are representative traces of charge
movement currents during the test-pulse phase of the
pulse protocol elicited from a holding potential of –80 mV
to a test potential of 160 mV for 50 ms. Charge move-
ment versus voltage curves were ﬁt with Eq. 1 with the
following parameters (Qmax in fC/pF, V1/2 in mV, and k in
mV, respectively); for a1S(E1014K), 5.3, 8.2, and 19.1;
for a1C(E736K), 5.9, 2.7, and 17.6; for a1C(E736K)/a1S
II-III, 5.7, 10.6, and 20.1; for a1C(E736K)/a1S all loop,
4.4, 12.0, and 17.6; and for nontransfected dysgenic
myotubes (shaded traces): 1.4, 7.0, and 12.9. For a ﬁt of
parameters by cell and number of cells included in the ﬁt,
see Table 2.
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presented in the histograms at the bottom of each panel.
Ca21 current density and Ca21 transient amplitude at 130
mV, at two Cd21 concentrations, were normalized to the
mean Ca21 current and Ca21 transient amplitude in control
solution. In all cases, there was a signiﬁcant decrease in
fractional Ca21 current density at 104 M Cd21. However,
only in the case of the a1C/a1S II-III loop chimera did we
observe a concomitant decrease in fractional Ca21 transient
amplitude. This was not the case for WT a1S or the a1C/
a1S all loop chimera. A statistical analysis of the parameters
of Ca21 conductance and cell ﬂuorescence in the presence of
Cd21 are described in Table 3. The Ca21 ﬂuorescence data in
Table 3 are in agreement with the statistical analysis of the
data at a single potential presented in histogram form at the
bottom of Fig. 5. The DF/Fmax ﬁtted to cells expressing
the II-III loop chimera in 104 M Cd21, but not that of the
FIGURE 5 Cd21 block of Ca21-dependent EC coupling promoted by the II-III loop chimera. Columns show representative mdg myotubes expressing the
II-III loop and all loop chimeras. The left panel shows myotubes expressingWT a1S used as control. The top graphs correspond to population average current-
voltage curves for depolarizations of 500 ms from a holding potential of40 mV. Insets show representative Ca21 currents elicited at130 mV from a holding
potential of40 mV. With the exception of the bar graphs at the bottom, all shaded traces and shaded symbols are in 104 M CdCl2 added to the bath solution.
The middle graphs show population-averaged Ca21 transient-voltage relationships for depolarizations of 200 ms from a holding potential of 40 mV. Insets
correspond to the spatial integral of the confocal ﬂuorescence in DF/F units in response to a 200-ms depolarization to130 mV from a holding potential of40
mV. Fluorescence-voltage curves were ﬁt with Eq. 1. Curves were ﬁt with the following parameters (Fmax inDF/F units, V1/2 in mV, and k in mV, respectively):
for WT a1S in 0 Cd21, 2.5, 13.7, and 14.1; for WT a1S in 104 Cd21, 2.2, 3.0, and 8.2; for a1C/a1S II-III in 0 Cd21, 2.8, 2.8, and 4.7; for a1C/a1S II-III in
104 Cd21, 0.7, 17.0, and 13.5; for a1C/a1S all loop in 0 Cd21, 2.1, 1.7, and 10.9; for a1C/a1S all loop in 104 Cd21, 2.7, 15.6, and 9.3. For a ﬁt of
parameters by cell and number of cells included in the ﬁt, see Table 3. The bottom bar graphs correspond to normalized Ca21 currents (shaded bars) and
normalized DF/Fmax (black) in control solution without Cd21, external solution with 106 M CdCl2, and external solution with 10
4 M CdCl2. Ca
21 currents
at130 mV were normalized to the population averaged Ca21 current at130 mV in the absence of Cd21. DF/Fmax from a ﬁt of individual cells was normalized
to DF/Fmax from a ﬁt of the population average in the absence of Cd
21.
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all loop chimera, was signiﬁcantly lower relative to controls
in external solution with 106 M Ca21 or external solution
without Cd21. The results conﬁrmed that the E736K
mutation was not responsible for the weak EC coupling
recovered by the II-III loop chimera. Rather, the behavior of
the all loop chimera emphasized that a quantitative recovery
of the skeletal phenotype could not be achieved unless all
the cytosolic elements of a1S were present. It remains to be
determined in future work which cytosolic domains in
addition to the II-III loop are required for a quantitative
functional recovery.
DISCUSSION
Studies in mdg myotubes designed to investigate the
contribution of a1S to skeletal-type EC coupling have
concluded that the II-III loop is functionally unique
(11,12,14,16,17,25,30,32). Our results conﬁrmed this ob-
servation. However, it was not previously known if the
functional recovery produced by the a1S II-III loop was
comparable to that produced by WT a1S, or if multiple
cytosolic domains of a1S were necessary for a quantitative
recovery of the EC-coupling phenotype. Earlier studies (11)
did not provide a voltage-clamp analysis of the contribution
of the skeletal loops alone or in combination, and the more
recent studies have focused exclusively on domains within
the a1S II-III loop (16,17,25). The efﬁciency of EC-coupling
recovery by the a1S II-III loop is a signiﬁcant issue since
structural models suggest that the area of juxtaposition
between the a1S subunit and RyR1 is large, and therefore the
number of interaction sites is potentially large (5,6). The
EC-coupling triggering mechanism could thus be much more
complex than a single DHPR loop orchestrating SR Ca21
release. Sequence divergence between a1S and a1C is
mostly conﬁned to the long cytoplasmic domains rather than
the transmembrane repeats. Hence, it was reasonable to
expect that a a1C/a1S chimera carrying all the cytosolic
domains of a1S could recover the skeletal EC-coupling
phenotype quantitatively. We found that a large fraction of
the Ca21 transient expressed by the a1C/a1S II-III loop
chimera was eliminated when the pore mutation
a1C(E736K) was introduced to reduce the inward Ca21
current. This was not the case for the a1C/a1S chimera
carrying all the cytosolic domains of a1S. Furthermore, the
results were conﬁrmed using Ca21-conducting variants of
the same chimeras in which the inward Ca21 current was
blocked by a low concentration of Cd21. The a1C/a1S all
loop chimera, unlike the a1C/a1S II-III loop chimera,
rescued Ca21 transients of the same DF/Fmax regardless of
the presence of the pore mutation. When normalized by the
DHPR charge movement and compared to a1C/a1S all loop
and WT a1S (see Table 2 legend), the maximum Ca21
ﬂuorescence expressed by the II-III loop chimera was 0.166
0.04 Fmax/Qmax, compared to 0.45 6 0.13 Fmax/Qmax for
a1C/a1S all loop, and 0.55 6 0.08 Fmax/Qmax for
a1S(E1014K), or ;3-fold lower (t-test signiﬁcance, p ,
0.05). These ratios only have comparative value since it is
unlikely that all the DHPR charge movement is involved in
EC coupling (42). The observations lend themselves to the
conclusion that a conglomerate of cytoplasmic domains,
rather than the II-III loop alone, is necessary to restore nor-
mal EC-coupling function.
The Ca21 transient expressed by CSk3, the a1C/a1S II-III
loop chimera described by Tanabe et al. (11) was sub-
stantially reduced in the presence of inorganic blockers of the
inward Ca21 current. Ca21 ﬂuorescence-voltage relation-
ships for CSk3 have not been described (11,14); therefore, it
is difﬁcult to compare the two sets of results. However,
qualitatively the results are similar and indicate that both
II-III loop chimeras have a sizable EC-coupling component
unrelated to the skeletal phenotype. CSk3 consists of a1C(1–
787)/a1S(666–791)/a1C(923–2171), whereas our chimera
included eight additional residues, namely a1S(1–788)/
a1S(667–799)/a1C(931–2171). These differences may not
be signiﬁcant since critical determinants within the a1S II-III
loop have been mapped to the segment of residues 671–690
and 720–765 present in both chimeras (14,25). Furthermore,
charge movements expressed by both chimeras in dysgenic
myotubes are comparable (12) (Table 2). Hence, possible
differences in voltage-sensor densities, which could con-
ceivably affect the density of mechanically coupled RyR1
channels, are nonexistent. Interestingly, Ca21 ﬂuorescence-
voltage relationships have been published for GFP-CSk53,
an a1C/a1S chimera carrying the a1S II-III loop resi-
dues 720–765 deemed critical for skeletal-type EC coupling.
This chimera also has an N-terminal fusion of the green
TABLE 3 Ca21 conductance and Ca21 transients expressed by a1C/a1S chimeras in presence of extracellular cadmium
Gmax(pS/pF) V1/2(mV) k (mV) DF/Fmax V1/2 (mV) k (mV)
WT a1S 1 104 Cd21 43 6 4 (7) 18 6 4 6.7 6 2.0 2.2 6 0.5 (9) 0 6 3 6.9 6 1.7
WT a1S 1 106 Cd21 158 6 15* (6) 11 6 2 3.8 6 0.3 3.4 6 0.6 (7) 3 6 3 5.8 6 0.4
a1C/a1S II-III 1 104 Cd21 53 6 8 (5) 14 6 4 10.1 6 3.6 0.7 6 0.3* (7) 16 6 3* 13.0 6 2.0*
a1C/a1S II-III 1 106 Cd21 211 6 9* (4) 2 6 6 5.4 6 3.3 1.4 6 0.6 (4) 13 6 9 5.1 6 0.7
a1C/a1S all loop 1 104 Cd21 29 6 8 (6) 38 6 14 20.1 6 5.8* 2.8 6 0.7 (6) 18 6 4* 10.6 6 2.2
a1C/a1S all loop 1 106 Cd21 104 6 9* (5) 6 6 3 5.2 6 1.6 2.4 6 0.4 (5) 5 6 4 6.9 6 1.9
Values are mean 6 SEM of Boltzmann parameters ﬁtted to each cell, with the number of cells indicated in parentheses. Gmax or DF/Fmax, V1/2, and k are
parameters of the Boltzmann ﬁt to each cell with Eq. 1.
*Parameters with one-way ANOVA signiﬁcance p , 0.05 compared to WT a1S 1 104 Cd21.
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ﬂuorescent protein (GFP). The Fmax expressed by GFP-
CSk53 was considerably lower than that expressed by the
GFP-WT a1S fusion even in external solution containing
the standard 10 mM Ca21 (31). Thus, the low Fmax of a II-III
loop chimera may not be related in all instances to the
presence of an enlarged Ca21-dependent EC-coupling
component, which is removed when the inward Ca21 current
is blocked. It could be that in this case, the GFP moiety
hinders EC coupling in the CSk53 chimera, or that residues
720–765 are insufﬁcient for a quantitative EC-coupling
recovery comparable to that of WT a1S. In support of the
latter, it is important to note that the identiﬁcation of critical
a1S II-III loop residues 720–765 in chimeras without GFP
was achieved at the expense of a substantial loss in Ca21
transient amplitude relative to the Ca21 transient expressed
by the parent CSk3 chimera carrying the complete a1S II-III
loop (14). Thus, an appropriate structural context is essential
for a quantitative recovery of EC-coupling function.
It was intriguing to ﬁnd that, on average, the shape of the
ﬂuorescence-voltage curve for the Ca21-conducting and
pore-mutant variants of the a1C/a1S II-III loop chimera
were both sigmoidal (Fig. 3). A somewhat bell-shaped curve
was expected for the former based on the signiﬁcant
dependence on the Ca21 current for triggering release. We
considered the possibility that the reduction in DF/Fmax
observed in the pore-mutant variant of the II-III loop chimera
reﬂected inactivation of the voltage sensor due to the
elimination of a critical Ca21-binding site (41). Several
reasons argue against this possibility. First, the pore mutation
a1S(E1014K) was shown to eliminate high-afﬁnity Ca21
binding to the subunit (39). Yet, WT a1S and a1S(E1014K)
had ﬂuorescence-voltage characteristics that were superim-
posable (Fig. 1). Second, the Ca21-conducting and pore-
mutant variants of the a1C/a1S all loop chimera expressed
skeletal-type EC coupling with a similar DF/Fmax (Tables 1
and 2). This was not expected under the assumption that the
pore mutation inactivated the voltage sensor. Finally, and
most signiﬁcantly, a reduction in DF/Fmax was observed in
the Ca21-conducting a1C/a1S II-III loop chimera when the
Ca21 current was blocked by Cd21. This was not observed
for WT a1S, nor for the a1C/a1S all loop chimera (Fig. 5).
Hence, it could not be argued that Cd21 block limited access
of Ca21 to the binding site on the voltage sensor. We further
searched for an explanation in the data itself. A cell-by-cell
ﬁt of the ﬂuorescence-voltage curve indicated that some cells
expressing the Ca21-conducting II-III loop chimera dis-
played a slight bell-shaped voltage dependence (three out of
seven) whereas others did not (four out of seven). This
heterogeneity contributed to the much larger variance of the
data collected for the II-III loop chimera relative to other
single-loop chimeras (see Fig. 2). A freeze-fracture analysis
of mdg myotubes expressing the CSk3 chimera revealed
that only a few of the chimeric DHPR particles present
at a DHPR-RyR1 junction were arranged as tetrads (43).
DHPR tetrad formation is a precondition for skeletal-type EC
coupling (1). Hence, junctions with tetrads are more likely to
trigger Ca21 release by a skeletal-type mechanism whereas
junctions without tetrads, or with ‘‘incomplete’’ tetrads, are
more likely to trigger Ca21 release via the Ca21 current. We
suggest that in myotubes expressing the II-III loop chimera,
the EC-coupling mechanism itself may be heterogeneous
due to a variable density of tetrads in each DHPR-RyR1
junction. The voltage dependence of the Ca21 transient may
approximate a sigmoidal relationship when the number of
skeletal-like junctions in a muscle cell is high and bell-
shaped when it is low. In addition, it is necessary to realize
that the Ca21-entry dependent component, in the best of
circumstances, is small. This can be appreciated by compar-
ing the maximum Ca21 transient amplitudes expressed by
WT a1S and WT a1C in Fig. 1. Such a component may not
be always possible to detect, particularly when the voltage-
dependent component is much larger.
The presence of a Ca21-entry-dependent EC-coupling
component in the a1S II-III loop chimera and not in the
chimera carrying all the cytosolic domains of a1S, strongly
suggests that structural determinants unknown at this point
contribute to the stability of the DHPR-RyR1 complex. The
mechanism by which the II-III loop in combination with
other cytoplasmic domains of a1S enable the formation of a
stable DHPR-RyR1 complex remains to be understood.
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